Flurry Of Drug Pricing Bills Offer US Congress Range Of Policy Options
Executive Summary
If pharma got to choose, it would pick the bills that seek to discourage price increases instead of the ones that allow the government to negotiate drug prices or use international reference pricing. It is unclear whether any legislation will pass, but without a Republican majority in the Senate, the risk for industry has never been greater.
You may also be interested in...
PhRMA’s ‘Better Way:’ Remember COVID Success, Tweak Part B, And Bash HR 3
Trade group’s new agenda offers few original solutions to tackle US drug costs, relying on old standbys and reminders of what medical innovation might be lost if industry is financially targeted by policy makers with a strong nod to drug manufacturers role the current pandemic.
Aurinia’s Dosing Patent For Lupkynis A ‘Slippery Slope’ To Extending US Market Exclusivity?
The Institute for Clinical and Economic Review raises concerns about the cost implications of companies obtaining extended market exclusivity by patenting the treatment protocol used for drugs in clinical trials.
Becerra Takes The Helm At HHS; More Visibility On Administration’s Drug Pricing Priorities To Follow
Becerra’s HHS has a new crop of former Capitol Hill staffers in its policy ranks who are well versed on legislation in the health care realm, including prescription drug pricing reform. That will help advance the Administration’s agenda.